This multicenter retrospective real-world study aims to evaluate the safety, efficacy and survival outcomes of neoadjuvant/induction immunotherapy in patients with non-small cell lung cancer (NSCLC). The study covers diverse treatment pathways, including surgery, definitive radiotherapy, and non-surgical strategies. It addresses gaps in existing trials by establishing a comprehensive cohort spanning neoadjuvant/induction therapy, perioperative management, and follow-up, providing real-world evidence to support treatment decisions in both operable and inoperable cases.
Histologically confirmed non-small cell lung cancer (NSCLC), regardless of the presence of EGFR or ALK sensitive driver gene mutations;
Clinical staging of IA-IIIC according to the AJCC 8th Edition before neoadjuvant treatment;
Received at least one cycle of neoadjuvant immunotherapy (with or without chemotherapy);
Assessed as resectable or potentially resectable by surgical experts prior to treatment.
Confirmed M1 disease;
History of previous lung malignancy or other metastatic malignant tumors;
Participation in other randomized controlled trials involving neoadjuvant treatment;
Significant missing clinical data.
Peking University Cancer Hospital & Institute
Lead sponsor